NCT00493467 2022-09-15
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT01549886 2021-10-04
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00491491 2020-08-31
Zevalin-beam for Aggressive Lymphoma
Sheba Medical Center
Phase 3 Completed
NCT00582166 2019-12-13
Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance
University of Wisconsin, Madison
Phase 2 Terminated
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed